development of a subunit vaccine for contagious bovine pleuropneumonia in africa
DESCRIPTION
Presented by Jan Naessens at the ILRI BioSciences Day, Nairobi, 27 November 2013TRANSCRIPT
Development of a subunit vaccine for contagious bovine pleuropneumonia in Africa
Jan Naessens
ILRI BioSciences Day, Nairobi, 27 November 2013
Funding body: IDRC-CIDA (CIFSFR grant)
Full Title: Development of a subunit vaccine for contagious bovine pleuropneumonia in Africa.
Short Title: Vaccine for CBPP
Institutes: VIDO, SaskatoonKARI Vet Res Centre, MugugaKARI Biotech, NairobiILRI, Nairobi
Important to ILRI: contribute to the following CGIAR goal and priorities “Animal health research to develop low-cost vaccines and diagnostic tools appropriate for smallholders”
Recipients of outcome: contribution to a better vaccine will directly benefit livestock keepers in areas with CBPP and national veterinary services that are responsible for disease monitoring and vaccination
Howe will it change their lives? Better productivity, reduced trade restrictions.
State of the problem? Distribution of CBPP in Africa
One of the most important livestock diseases in Africa (AU-IBAR, OIE)
Affects 24 m people in low income countries
Cost?
How will this project change the outcomes?
A vaccine will reduce the cost of cattle farming and help to reduce trade restrictions.
Links to ILRI’s SLO’s?
- Reduced rural poverty for the livestock keepers
- Improved food security, as more livestock products are available at lower cost
Hypothesis
Antibodies to proteins from mycoplasma can protect
Approach
Use bio-informatics to select 75 potential vaccine antigens (mycoplasma molecules that are secreted or present on the surface)
Produce the recombinant proteins
Use these proteins to immunize cattle and check their capacity to protect the host after challenge.
Innovation?
Systemic approach
Direct result
% animals average lung with symptoms lesion score
Non-immunized 70 1.3 (± 0.9)
Live vaccine 13 0.3 (± 0.7)
Heat-inactivated 38 0.5 (± 0.7)
Formalin-fixed 57 2.0 (± 2.3)
Conclusions:
1. It is possible to induce protection with inactivated material. Live mycoplasma are not necessary.
2. Protection is not correlated with antibody titre against whole mycoplasma.
3. The way the antigen is presented and delivered plays a major role.
Exp. Number date first dateags cattle immunization challenge end
1 25 60 03-10-2013 07-11-2013 01-20142 25 60 09-12-2013 14-01-2014 03-20143 16 50 04-02-2014 18-03-2014 05-2014
Future steps?
If we find that a pool of proteins protect:- confirm & identify protein- optimize delivery - adjuvant/doses
- period of immunity - efficacy
- minimum dose
If we have a potential vaccine:- roll out and adoption strategy (IDRC-funding)
(together with pox virus project - OVI/Alberta)
What support do you expect from ILRI and the BioScience Directorate?
I did not expect directorate to do muchbut I hope they support to continue this project to the end
better lives through livestock
ilri-org